3Dバイオプリンティングの世界市場：2025年～2033年

世界の3Dバイオプリンティングの市場規模は、2024年に34億5,000万米ドルとなりました。同市場は、2033年には302億8,000万米ドルに達し、予測期間の2025年～2033年のCAGRは24.2％になると予測されています。

3Dバイオプリンティングは、デジタルモデルを使用して3次元構造を作成する高度な製造技術です。ヘルスケア、自動車、航空宇宙などの産業で利用されています。3Dプリンティングの一分野であるバイオプリンティングは、バイオインクを層ごとに堆積させ、生きた細胞と生体材料を組み合わせて組織のような構造を作り出します。この技術は、再生医療、薬物検査、臓器移植研究において可能性を秘めています。この技術は、再生医療、薬物検査、臓器移植研究などに応用される可能性があります。

世界の3Dバイオプリンティング市場は、組織工学と再生医療の進歩によって牽引されています。バイオプリンティング技術は、皮膚、軟骨、ミニチュア臓器のような複雑な組織構造の作成を可能にし、薬物試験、疾患モデリング、臓器移植の可能性を提供します。こうした技術革新は動物実験を減らし、個別化治療を加速させる。研究機関やバイオテクノロジー企業が多額の投資を行う中、バイオプリンターやバイオインクの需要は伸びると予想されます。

例えば、2024年4月、China University of Petroleum、Zhejiang University、Tel Aviv Universityは、複雑な生物学的構造や臓器を開発するためのペプチド自己組織化技術と3Dプリンティングの使用を探求し、将来の生物医学の応用の基礎を築きました。

世界の3Dバイオプリンティング市場は、安全性、同意、誤用に対する懸念から、規制および倫理的課題に直面しています。既存の規制の枠組みは不十分なことが多く、商業化や臨床導入の遅れにつながっています。この不確実性は、特に医療規制が厳しい地域での投資や技術革新を妨げ、市場拡大に影響を与える可能性があります。

当レポートでは、世界の3Dバイオプリンティング市場について調査し、市場の概要とともに、コンポーネント別、技術別、用途別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第4章 戦略的洞察と業界展望

• 市場のリーダーとパイオニア
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第5章 3Dバイオプリンティング市場（コンポーネント別）

• 3Dプリンター
• 生体材料
• 足場

第6章 3Dバイオプリンティング市場（技術別）

• インクジェットベースのバイオプリンティング
• 磁気浮上
• 注射器ベースのバイオプリンティング
• レーザーベースのバイオプリンティング
• その他

第7章 3Dバイオプリンティング市場（用途別）

• 静脈穿刺補助
• 医薬品
• 補綴物とインプラント
• 歯科
• バイオセンサー
• 消費者/個人向け製品テスト
• バイオインク
• 食品および動物用製品

第8章 3Dバイオプリンティング市場（エンドユーザー別）

• 研究機関および学術機関
• バイオ医薬品企業
• 病院
• その他

第9章 3Dバイオプリンティング市場、地域市場分析および成長機会

• 北米
  • 地域特有の主要な動向
    • 米国
    • カナダ
    • メキシコ
• 欧州
  • 地域特有の主要な動向
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
• 南米
  • 地域特有の主要な動向
    • ブラジル
    • アルゼンチン
    • その他
• アジア太平洋
  • 地域特有の主要な動向
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
• 中東・アフリカ
  • 地域特有の主要な動向

第10章 競合情勢と市場ポジショニング

• 競合状況の概要と主要市場参入企業
• 市場シェア分析とポジショニングマトリックス
• 戦略的パートナーシップ、合併・買収
• 製品ポートフォリオとイノベーションにおける主な発展
• 企業ベンチマーク

第11章 企業プロファイル

• 3D Systems Corporation
• 会社概要
• 製品ポートフォリオ
• 財務概要
• 主な発展
• SWOT分析
• EnvisionTEC GmbH
• Stratasys Ltd
• Cyfuse Biomedical KK
• Cellink
• Poietis
• RegenHU SA

第12章 仮定と調査手法

第13章 付録

The global 3D bioprinting market reached US$ 3.45 billion in 2024 and is expected to reach US$ 30.28 billion by 2033, growing at a CAGR of 24.2% during the forecast period 2025-2033.

3D bioprinting is are advanced manufacturing technologies that create three-dimensional structures using digital models. They are used in industries like healthcare, automotive, and aerospace. Bioprinting, a specialized branch of 3D printing, involves layer-by-layer deposition of bioinks, combining living cells and biomaterials to create tissue-like structures. This technology has potential in regenerative medicine, drug testing, and organ transplantation research. Together, they revolutionize product design and manufacturing, offering enhanced precision, customization, and innovation.

Market Dynamics: Drivers & Restraints

Advancements in Tissue Engineering and Regenerative Medicine

The global 3D bioprinting market is driven by advancements in tissue engineering and regenerative medicine. Bioprinting technologies enable the creation of complex tissue structures like skin, cartilage, and miniature organs, offering the potential for drug testing, disease modeling, and organ transplantation. These innovations reduce animal testing and accelerate personalized therapies. As research institutions and biotech companies invest heavily, demand for bioprinters and bioinks is expected to grow.

For instance, in April 2024 by China University of Petroleum, Zhejiang University, and Tel Aviv University explored the use of peptide self-assembly technology and 3D printing for developing complex biological structures and organs, laying the foundation for future biomedical applications.

Regulatory and Ethical Challenges

The global 3D bioprinting market faces regulatory and ethical challenges due to concerns about safety, consent, and misuse. Existing regulatory frameworks are often inadequate, leading to delays in commercialization and clinical adoption. This uncertainty can hinder investment and innovation, especially in regions with stricter medical regulations, affecting market expansion.

Segment Analysis

The global 3D bioprinting market is segmented based on component, technology, application, end-user, and region.

Component:

The 3D printers from the component segment are expected to dominate the 3D bioprinting market with the highest market share

3D printers are advanced devices that use additive manufacturing to create intricate biological structures by depositing bio-inks layer by layer. These bioinks, often containing living cells, biomaterials, and growth factors, mimic natural human tissues and organs. They are widely used in regenerative medicine, drug development, and disease modeling, enabling researchers to study cellular behavior and develop personalized treatments.

The global demand for 3D printers is driven by the growing demand for organ and tissue transplants, regenerative medicine investments, and personalized healthcare. Advancements in biomaterials and bioprinting technologies have improved tissue precision, expanding their use in clinical and research settings. Government support, regulatory developments, and partnerships between research institutes and biotech companies are also driving this growth.

For instance, in November 2024, University of Melbourne biomedical engineers developed a 3D bioprinter capable of creating structures that resemble various human body tissues, including soft brain tissue and harder materials like cartilage and bone.

Geographical Analysis

North America is expected to hold a significant position in the 3D bioprinting market with the highest market share

North America dominates the global 3D bioprinting market due to strong research, robust healthcare infrastructure, and early adoption of advanced technologies. The presence of biotech companies, research institutions, and universities in tissue engineering and regenerative medicine has accelerated bioprinting innovation. Government funding and regulatory frameworks, particularly in the U.S., promote 3D printing for medical applications like prosthetics, implants, and personalized healthcare solutions. The growing demand for organ transplantation alternatives and personalized medicine further drives the use of bioprinting technologies.

For instance, in June 2024, Tethon 3D, a Nebraska-based ceramic 3D printing specialist, launched the Bison Bio DLP 3D printer, a desktop-sized system designed for medical R&D applications. The system is compatible with Tethin 3D's Tethon LAP photoinitiator and Tethon GelMA hydrogel bioink, produced in partnership with Cell Bark Innovation, a biomaterial firm.

Competitive Landscape

The major global players in the 3D Bioprinting market include 3D Systems Corporation, EnvisionTEC GmbH, Stratasys Ltd, Cyfuse Biomedical KK, Cellink, Poietis, and RegenHU SA, among others.

Key Developments

• In November 2024, SCTIMST developed India's first Indigenous patented bioink formulation for fabricating liver, kidney, pancreas, skin, brain, and heart tissues using advanced 3D bioprinting technology, using advanced 3D printing technology.

Why Purchase the Report?

• Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global 3D bioprinting market report delivers a detailed analysis with 70 key tables, more than 74 visually impactful figures, and 165 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Component
• 2.4. Snippet by Technology
• 2.5. Snippet by Application
• 2.6. Snippet by End User
• 2.7. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Advancements in Tissue Engineering and Regenerative Medicine
    • 3.1.1.2. Growing Adoption in Pharmaceutical and Cosmetic Industries
  • 3.1.2. Restraints
    • 3.1.2.1. Regulatory and Ethical Challenges
    • 3.1.2.2. Lack of Qualified Professionals
  • 3.1.3. Opportunity
    • 3.1.3.1. Rise in Personalized Medicine and Drug Testing
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with largest largest-selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. Latin America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Force Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. By Component

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 5.1.2. Market Attractiveness Index, By Component
• 5.2. 3D Printers*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. Biomaterials
• 5.4. Scaffolds

6. 3D Bioprinting Market, By Technology

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 6.1.2. Market Attractiveness Index, By Technology
• 6.2. Inkjet-Based Bioprinting*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Magnetic Levitation
• 6.4. Syringe-Based Bioprinting
• 6.5. Laser-Based Bioprinting
• 6.6. Others

7. 3D Bioprinting Market, By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Venipuncture Assistance*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Medical Pills
• 7.4. Prosthetics and Implants
• 7.5. Dental
• 7.6. Biosensors
• 7.7. Consumer/Personal Product Testing
• 7.8. Bioinks
• 7.9. Food and Animal Products

8. 3D Bioprinting Market, By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Research Organizations and Academic Institutes*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Biopharmaceutical Companies
• 8.4. Hospitals
• 8.5. Others

9. 3D Bioprinting Market, Regional Market Analysis and Growth Opportunities

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.7.1. U.S.
    • 9.2.7.2. Canada
    • 9.2.7.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.7.1. Germany
    • 9.3.7.2. U.K.
    • 9.3.7.3. France
    • 9.3.7.4. Spain
    • 9.3.7.5. Italy
    • 9.3.7.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.7.1. Brazil
    • 9.4.7.2. Argentina
    • 9.4.7.3. Rest of Latin America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.7.1. China
    • 9.5.7.2. India
    • 9.5.7.3. Japan
    • 9.5.7.4. South Korea
    • 9.5.7.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape and Market Positioning

• 10.1. Competitive Overview and Key Market Players
• 10.2. Market Share Analysis and Positioning Matrix
• 10.3. Strategic Partnerships, Mergers & Acquisitions
• 10.4. Key Developments in Product Portfolios and Innovations
• 10.5. Company Benchmarking

11. Company Profiles

• 11.1. 3D Systems Corporation*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals, etc.
  • 11.1.5. SWOT Analysis
• 11.2. EnvisionTEC GmbH
• 11.3. Stratasys Ltd
• 11.4. Cyfuse Biomedical KK
• 11.5. Cellink
• 11.6. Poietis
• 11.7. RegenHU SA

LIST NOT EXHAUSTIVE

12. Assumptions and Research Methodology

• 12.1. Data Collection Methods
• 12.2. Data Triangulation
• 12.3. Forecasting Techniques
• 12.4. Data Verification and Validation

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us